KRAS and familial pancreatic carcinoma: Mukhopadhyay Mukhopadhyay S S Undermining Glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers Undermining Glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers Cancer Res.